Australian Biotech industry confident, despite economic woes

18 April 2012

The annual Biotechnology Industry Position Survey shows the bullish sentiment for the Australian industry’s future continues, while the operating environment (economic and public policy) remains a concern. The survey was undertaken by AusBiotech and Grant Thornton Australia.

The industry’s confidence, reported in 2011, continues with 82% of respondents expecting their business to grow in the coming year, while 68% characterised last year as a good or excellent year. The expansionary approach to employment that emerged during 2009 persists with a majority of companies (58%) indicating they will increase staffing numbers in the coming year.

However, the Australian operating environment (economic and public policy) remains a concern for the growth of biotechnology companies, with two in five companies (38%) saying it was working against their growth.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Biotechnology